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Abstract
Background: Multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE) are
debilitating neuroinflammatory diseases mediated by lymphocyte entry into the central nervous system (CNS).
While it is not known what triggers lymphocyte entry into the CNS during neuroinflammation, blockade of
lymphocyte migration has been shown to be effective in controlling neuroinflammatory diseases. Since we have
previously shown that extracellular adenosine is a key mediator of lymphocyte migration into the CNS during EAE
progression, we wanted to determine which factors are regulated by adenosine to modulate EAE development.
Methods: We performed a genetic analysis of wild type and CD73−/− (that are unable to produce extracellular
adenosine and are protected from EAE development) to identify factors that are both important for EAE
development and controlled by extracellular adenosine signaling.
Results: We show that extracellular adenosine triggered lymphocyte migration into the CNS by inducing the
expression of the specialized chemokine/adhesion molecule CX3CL1 at the choroid plexus. In wild type mice,
CX3CL1 is upregulated in the brain on Day 10 post EAE induction, which corresponds with initial CNS lymphocyte
infiltration and the acute stage of EAE. Conversely, mice that cannot synthesize extracellular adenosine
(CD73−/− mice) do not upregulate CX3CL1 in the brain following EAE induction and are protected from EAE
development and its associated lymphocyte infiltration. Additionally, blockade of the A2A adenosine receptor
following EAE induction prevents disease development and the induction of brain CX3CL1 expression. The CX3CL1
induced during EAE is found on the choroid plexus, which is the barrier between the blood and cerebral spinal
fluid in the brain and is a prime entry point into the CNS for immune cells. Furthermore, CX3CL1 expression can be
induced in the brains of mice and in choroid plexus cell line following A2A adenosine receptor agonist
administration. Most importantly, we show that CX3CL1 blockade protects against EAE development and inhibits
lymphocyte entry into the CNS.
Conclusions: We conclude that extracellular adenosine is an endogenous modulator of neuroinflammation during
EAE that induces CX3CL1 at the choroid plexus to trigger lymphocyte entry into the brain.
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Background
Lymphocyte migration into the central nervous system
(CNS) is a highly regulated process. Due the potential
harmful side effects of inflammation within the brain,
many safeguards have evolved to protect the brain from
immune mediated damage. For example, anatomical
obstacles, such as the blood brain barrier (BBB), prevent
the migration of lymphocytes across cerebral blood ves-
sels [1,2]. Additionally, due to the lack of cell-mediated
antigen drainage from the brain (the afferent arm of
adaptive immunity), brain derived antigens/cells are pre-
vented from priming and activating peripheral T cells
[3]. However, migration of lymphocytes into the CNS
can occur in response to cellular damage from trauma,
bacterial and viral infections, and autoimmune diseases.
Since even a small amount of brain damage can have
serious or fatal consequences for an individual, there is a
delicate balance between initiating an immune response
within the brain and quickly controlling it before by-
stander damage occurs. Although animal models of neu-
roinflammation have helped to determine which cell
types are involved in the brain’s immune response, what
promotes the focused migration of lymphocytes into the
CNS during an inflammatory attack is not clearly
understood.
There are many diseases associated with inflammation
in the CNS (including meningitis, encephalitis, cerebritis
and encephalomyelitis, etc..). One of the most common
neuroinflammatory disorders is multiple sclerosis (MS)
[4], a chronic autoimmune inflammatory disease of the
CNS that affects more than 2.5 million people world-
wide [5]. In patients with MS, loss of neurological func-
tion occurs following the demyelination of axons which
is mediated by infiltrating autoreactive immune cells.
Typically, most patients suffer from a relapsing remitting
form of MS, with the disease progressively becoming
more debilitating over time. While MS relapses are com-
monly associated with increased lymphocyte infiltration
into the brain and spinal cord, what triggers relapse is
not understood. Interestingly, bacterial and viral infec-
tions have been implicated in the initiation and persist-
ence of autoimmune diseases [6], including MS [7-9].
Treatments for MS include curtailing the immune re-
sponse (mitoxantrone, an immunosuppressant or glatira-
mer acetate, an immunomodulator), preventing immune
cell migration (natalizumab, blocks alpha-4 integrin
lymphocyte binding), or inhibiting viral replication
(interferon-beta; its effects might also be through immu-
nomodulation) [10,11]. Unfortunately, these treatments
only reduce the rate of progression of MS, but do not
ameliorate it. Therefore, a better understanding of the
events which trigger lymphocyte infiltration into the
CNS prior to disease relapse is necessary in order to de-
sign treatments to halt disease progression.
One potential trigger for immune cell infiltration into
the CNS is cell damage. When cells are damaged, extra-
cellular factors are released to communicate the trauma
to surrounding cells. An example of such a factor is ATP.
Upon damage to a cell membrane, intracellular ATP is
released into the extracellular space [12,13]. This ATP
can be hydrolyzed into AMP and then to adenosine by
the action of the extracellular enzymes CD39 and CD73,
respectively [14]. Nearby cells that express any of the
four G-protein coupled adenosine receptor subtypes
(A1, A2A, A2B, or A3) can respond to the local damage
[14,15]. The type of response following the activation of
adenosine receptors depends on the responding cell and
the adenosine receptors which it expresses. For example,
within the lung increased extracellular adenosine levels
during injury have been shown to induce cellular migra-
tion to promote repair [16]. However, immune cells are
typically inhibited by high local extracellular adenosine
levels in order to prevent excessive collateral damage to
healthy tissue that can result during an inflammatory re-
sponse [13,14,17,18]. Therefore, extracellular adenosine
is arguably an ideal candidate to regulate inflammation,
as it acts as a cell damage signal to promote cell migra-
tion to sites of tissue damage to promote repair, while
also acting as an immune modulator to regulate the
magnitude of the inflammatory response and lessen col-
lateral tissue damage [19].
Extracellular adenosine has also been shown to be
involved in mediating neuroinflammatory disease pro-
gression, in experimental autoimmune encephalomyelitis
(EAE), the animal model of MS [20]. Mice that have
been given adenosine receptor antagonists or lack the
ability to hydrolyze extracellular adenosine from AMP
(CD73−/−) are protected from EAE and exhibit dimin-
ished lymphocyte infiltration into the CNS [20], despite
the observation that lymphocytes from CD73−/− have a
more pro-inflammatory phenotype [20]. CD73 and the
A2A adenosine receptor are expressed in the brain on
endothelial cells [21,22] and the choroid plexus [19,20].
Interestingly, both CD73 and the A2A adenosine recep-
tor are more highly expressed on the choroid plexus
than elsewhere in the CNS. [20], sites known to be per-
missive to CNS lymphocyte entry [23,24]. We
hypothesize that damage in the form of released ATP
and its subsequent conversion to adenosine during EAE
progression is a danger signal to regulate lymphocyte
entry into the CNS.
In this study, we demonstrate that extracellular adeno-
sine regulates lymphocyte migration into the CNS during
EAE by modulating chemokine expression at the onset of
disease. In particular, extracellular adenosine induces the
expression of CX3CL1 in the CNS during EAE. CX3CL1
(also known as fractalkine) is a unique molecule that can
act both as an adhesion molecule (when membrane
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bound) and a chemoattractant (following cleavage) for
immune cells that express its cognate receptor CX3CR1
[25]. Interestingly, CX3CL1 has been shown to be
increased in the serum of patients with MS and other
CNS damage [26-28]. Here we show that CX3CL1
increases during EAE progression and can be inhibited
through A2A adenosine receptor antagonist treatment
(which protects against EAE). Additionally, A2A adeno-
sine receptor agonists induce CX3CL1 expression in the
brain and on the choroid plexus. Anti-CX3CL1 antibody
mediated blockade protects against EAE development
while also inhibiting cerebral lymphocyte infiltration.
These findings suggest that extracellular adenosine regu-




C57BL/6 and CX3CR1-GFP/GFP [29] mice were pur-
chased from The Jackson Laboratories. CD73−/− mice
have been previously described [30] and have been
backcrossed to C57BL/6. Mice were bred and housed
under specific pathogen-free conditions at Cornell
University. For adenosine receptor blockade experi-
ments, mice were given SCH58261 (1 mg/kg or 5 mg/kg
s.c.; Tocris) 1 day prior to EAE induction and every
3 days continuing throughout the experiment. For
adenosine receptor agonist experiments NECA (5'-N-
Ethylcarboxamidoadenosine) and CGS 21680 (Tocris)
were each dissolved in DMSO, diluted in PBS to the
desired concentration, and injected i.p. to mice to be
compared to vehicle control (DMSO/PBS) treated mice.
For anti-CX3CL1 experiments, mice were given either
daily rat anti-CX3CL1 IgG (4 μg/mouse, i.p.; R&D
Systems) or isotype rat IgG (eBioscience) antibody treat-
ment starting at Day 8 post EAE induction (MOG
immunization) until the end of the experiment. All
procedures performed on mice were approved by the
Cornell Committee for the Humane Use of Animals.
EAE induction and scoring
EAE was induced as previously described [31]. Briefly, a
1:1 emulsion of MOG35-55 peptide (1 mg/ml in PBS)
(Anaspec) and complete Freund’s adjuvant (CFA, Sigma)
was injected subcutaneously (50 μl) into each flank. Per-
tussis toxin (PTX, 20 ng) (Biological Laboratories Inc.)
was given intravenously (200 μl in PBS) at the time of
immunization and again two days later. Mice were scored
daily for EAE based on disease symptom severity; 0 = no
disease, 0.5 = weak tail (cannot curl tail completely), 1.0 =
limp tail (complete inability to move tail), 2 = limp tail
and partial hind limb paralysis, 3 = total hind limb paraly-
sis, 4 = both hind limb and fore limb paralysis, 5 = death.
Mice with a score of 4 were euthanized.
Choroid plexus cell culture and migration assay
The mouse choroid plexus cell line, CPLacZ-2 [32], was
grown in DMEM/F-12 media supplemented with 10%
Fetal Bovine Serum (FBS). CPLacZ-2 cells were grown
to confluency and treated with the adenosine receptor
A2A agonist CGS21680 for 2 hours and then harvested
for RNA extraction. For migration assays, CPLacZ-2
cells were grown to confluency on transwell inserts
(8 μm). Cells were then treated with CGS (100 nM)
for 24 hours. Meanwhile, migratory lymphocytes isolated
from the spleen were activated with con A (10 μg/ml) for
48 hours. Before adding migratory cells (2.5 X 106) in
to the upper chamber of the transwell, choroid plexus
cells were pre-treated with anti-CX3CL1 (1.5 μg/ml) for
1 hour. Lymphocytes were allowed to migrate overnight
with exogenous chemokine (SDF-1) added to bottom
chamber to induce migration.
Quantitative real-time PCR
Using Trizol (Invitrogen), RNA was isolated from both
mice and the CPLacZ-2 choroid plexus cell line. For
mouse samples, animals were anesthetized and perfused
with cold PBS through the left ventricle of the heart.
Brains were isolated and half of each brain was homoge-
nized in 2 ml of Trizol using the Omni THQ homogenizer
(Omni International, Kennesaw, GA). cDNA was synthe-
sized using a Reverse-iT kit (ABGene). Primers specific
for CX3CL1 (Forward: 5’-GTGCTGACCCGAAGGAG-
AAA-3’, Reverse: 5’- CACCCGCTTCTCAAACTTGC-3’)
were used to determine gene expression levels relative to
housekeeping gene levels using Kapa Sybr Fast (Kapa Bio-
systems) run on a BioRad CFX96 real time qPCR system.
In some instances (noted with hatched lines), comparisons
were made to control samples to determine fold change,
with controls values set to 1.0. Melt curve analyses were
performed to measure the specificity for each PCR product.
Flow cytometry
Cells were isolated from the spleen of naïve CX3CR1-
GFP/GFP mice and then incubated with ACK buffer (0.15
M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.3) to lyse
red blood cells. Cell suspensions were stained with
fluorochrome-conjugated monoclonal antibodies against
CD45 (lymphocyte marker, 30-F11), CD4 (RM4-5), CD8
(53–6.7), CD49b [Natural Killer NK marker, DX5], CD11b
(H35-17.2), CD11c (N418), F480 (macrophage marker,
BM8), and B220 (B-cell marker, RA3-6B2) (purchased
from eBioscience and BD Bioscience). Stained cells were
acquired on a FACS CantoII (BD Biosciences) and ana-
lyzed with FACS Diva software (BD Biosciences).
Immunostaining
Anesthetized mice were perfused with PBS, the brains
isolated, and half of the brain was snap frozen in Tissue
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Tek-OCT medium. Five micron sections (brains in a sa-
gittal orientation) were affixed to Supefrost/Plus slides
(Fisher), fixed in acetone, and stored at −80°C. For
immunostaining, slides were thawed, washed in PBS,
blocked with Casein (Vector) in normal goat serum
(Zymed), and then incubated with either fluorochrome-
conjugated or non-conjugated [subsequently stained
with a goat-anti rat biotin secondary antibody (Jackson
ImmunoResearch)] against CD45 , CD11b, F480, CD4,
CD8, CD11b, or CX3CL1 (MAB571, R&D Systems). For
fluorescent images, slides were mounted with Vecta-
shield mounting media with DAPI (Vector Laboratories).
For brightfield images, slides were stained with a biotin/
avidin-HRP complex (Invitrogen), developed with an
AEC (aminoethyl carbazole) HRP developing kit (Invi-
trogen), and counterstained with hemotoxylin. Images
were obtained on a Zeiss Axio Imager M1 fluorescent
microscope utilizing AxioVision software. Cell counts to
determine cellular infiltration were performed on ana-
tomically similar areas in the brain (i.e. cerebellum and
hippocampus) and spinal cord fields at 10x magnifica-
tion in each experimental mouse and then averaged to-
gether to determine mean cell infiltration per field. Cell
counts were performed by the same person for each
stain. For fluorescent images, the same exposure/image
capture settings were utilized for images taken within
the same fluorescent channel for each sample for each
specific antibody stain. Utilizing the AxioVision soft-
ware, brightness and contrast settings (via AxioVision
min/max calculation) were similar among the samples
within the same fluorescent channel/antibody stain.
Statistical analyses
Statistical differences between EAE treatment groups
were determined utilizing two-way ANOVA analysis.
The Student’s t-test was utilized for other comparisons
unless stated within the figure legends. Statistics were
calculated utilizing GraphPad Prism and Microsoft Excel
software. Statistical differences were determined where
P ≤ 0.05.
Results
Extracellular adenosine induces CX3CL1 expression in the
brain during EAE
Although lymphocyte infiltration into the CNS is
required for EAE/MS development, it is not clearly
understood what factors regulate this transmigration.
Previously, we have shown that extracellular adenosine
is a key mediator of lymphocyte migration into the CNS
during EAE progression [20]. For instance, mice lacking
the ability to hydrolyze extracellular AMP into extracel-
lular adenosine (CD73−/− mice) were protected from
myelin oligodendrocyte peptide (MOG) induced EAE
development compared to wild type mice (Figure 1A
and Table 1) and its associated CNS lymphocyte infiltra-
tion (Figure 1B). To identify genes that may be regulated
by extracellular adenosine in the brain during EAE pro-
gression, we analyzed gene expression of 27 EAE-
relevant [33,34] chemokines, chemokine receptors, and
adhesion molecules in wild type compared to CD73−/−
mice by quantitative real-time PCR (Figure 1C). This
detailed study was performed over a time course (Days
5, 10, 14, 21) post-EAE induction. Of the genes analyzed,
21 were differentially expressed at some point during
EAE progression (Figure 1C). Of these, CCL12, CXCL9,
CXCL10, CX3CL1, CCR1, CCR7, CXCR3, CXCR4, and
ICAM1 were increased more than 5 fold in the brains of
wild type compared to CD73−/− mice at day 10 post
EAE induction (Figure 1C), a critical time point asso-
ciated with disease onset (Table 1) and initial CNS
lymphocyte infiltration [23]. No differences were
observed in CCL2, CCL19, CCL20, CXCL2, CXCL11,
and CCR6 gene levels (data not shown).
To determine if the expression of these tested genes
could be regulated by extracellular adenosine mediated
signaling, we treated wild type mice with NECA, a broad
spectrum adenosine receptor agonist, and assessed
changes in gene expression 4 hours post-treatment com-
pared to vehicle controls (Figure 1D). Only CXCL1,
CX3CL1, CCR3, and CCR7 were upregulated in the brains
of wild type mice following NECA treatment, with
CX3CL1 showing the highest fold increase compared to
vehicle treated wild type mice (Figure 1D). As stated
above, CX3CL1 was one of the genes identified as being
expressed strikingly higher levels in wild type compared to
CD73−/− mice during the EAE progression (Figure 1C).
Taken together, these results suggest that adenosine recep-
tor signaling triggered by extracellular adenosine hydro-
lyzed from AMP by CD73 induces the expression of the
chemokine/adhesion molecule CX3CL1 in the brain dur-
ing EAE progression.
CX3CL1 expression in the brain is regulated by the A2A
adenosine receptor
Previously, we have shown that the A2A adenosine re-
ceptor signaling is involved in controlling EAE progres-
sion and lymphocyte infiltration into the CNS [20]. To
determine if A2A adenosine receptor signaling regu-
lates CX3CL1 expression, we performed dose response
studies in mice with the selective A2A adenosine re-
ceptor agonist CGS21680 and quantified the gene ex-
pression of CX3CL1 in the brain (Figure 2A). Mice
that received CGS21680 showed significant increases in
brain CX3CL1 expression over a wide range of doses
(0.1 mg/kg – 10 mg/kg) compared to vehicle treated
controls (Figure 2A). To determine if A2A adenosine
receptor signaling regulates CX3CL1 expression during
EAE progression, we treated MOG-induced EAE mice
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with the A2A adenosine receptor specific antagonist
SCH58261 (Figure 2B-D). Similar to CD73−/− mice
[20], SCH58261 treated mice are protected from EAE
development and its associated CNS lymphocyte infil-
tration (Figure 2B-C). Consistent with this disease pro-
tection, genetic analysis of A2A adenosine receptor
antagonist treated mice showed no alterations in brain
CX3CL1 expression, while vehicle treated mice dis-
played increased CX3CL1 levels at day 10 post-EAE in-
duction (Figure 2D). These results strongly suggest that
A2A adenosine receptor activation, which typically only
occurs in vivo in environments with high concentrations
Figure 1 Chemokine, chemokine receptor, and adhesion molecule genetic expression in the brains of wild type and CD73−/− mice
following EAE induction. (A) EAE disease profile of wild type (n = 8) and CD73−/− mice (n = 10). Error bars represent the s.e.m. Significant
differences are indicated as determined by two-way ANOVA. EAE data is combined from 2 separate experiments. (B) CD45 and CD4 stained
frozen brain sections (cerebellum) from day 14 post-EAE induction wild type and CD73−/− mice. Positively stained cells (red) are shown against a
hematoxylin counterstain (blue). Black scale bars represent 50 μm. (C) Brain gene expression from wild type and CD73−/− mice with EAE over
time (n = 5 mice per group) as determined by quantitative real-time PCR. Gene levels were normalized to GAPDH levels and displayed in a heat
map as a ratio of wild type to CD73−/− to determine fold differences in expression at each time point. (D) Brain gene expression from wild type
mice treated with the broad spectrum adenosine receptor agonist NECA (0.25 mg/kg) or DMSO vehicle control as determined by quantitative
real-time PCR 4 hours post treatment. Gene levels were normalized to GAPDH levels and displayed in a heat map as a ratio of NECA to vehicle
treated to determine fold differences in expression.
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of extracellular adenosine (such as during inflammation)
[35-37], can induce CX3CL1 expression in the brain.
CX3CL1 is upregulated in the CNS on the choroid plexus
during EAE progression
Because our data indicate that CX3CL1 increased in the
brain during EAE progression (Figure 1C and 3A), we
next wanted to determine the cerebral structure on
which this increase was occurring. Since CX3CL1 is
known to be expressed in a membrane bound adhe-
sion molecule form (before it is cleaved into a soluble
chemoattractant factor), we assessed its expression via
immunofluorescent staining in the brains of naïve and
post-EAE induced wild type mice (Figure 3B-M).
Based on this staining, CX3CL1 was found to be
expressed in naïve mice at low levels on the choroid
plexus (Figure 3B) and the hippocampal (Figure 3F)
and cerebellar (Figure 3J) areas. At day 10 post EAE
induction, when pronounced increases in CX3CL1
mRNA expression is observed (Figure 3A and 2D),
increased CX3CL1 expression is displayed at the chor-
oid plexus (Figure 3C), and to a lesser degree near the
hippocampus (Figure 3G). CX3CL1 expression at the
choroid plexus was still elevated at day 14 post EAE
induction (Figure 3D), but returned to naïve levels by
day 21 (Figure 3E) when disease recovery was evident.
Interestingly, CX3CL1 expression was not found on
endothelial cells (Additional file 1: Figure S1). Add-
itionally, no other changes in CX3CL1 expression was
observed in the other cerebral compartments during
EAE (Figure 3H-I, K-M).
Figure 2 CX3CL1 upregulation within the brain during EAE is associated with A2A adenosine receptor signaling. (A) CX3CL1 gene expression
(relative to DMSO vehicle) in the brains of wild type mice following 4 hour A2A adenosine receptor agonist CGS21680 treatment as determined by
quantitative real-time PCR. Error bars represent the s.e.m.; n ≥ 3 mice / treatment. Significant differences (P < 0.05, *; P < 0.001, ***) are indicated as
determined by the Student’s t-test. (B) EAE disease profile in wild type mice given either the A2A adenosine receptor antagonist SCH58261 (1 mg/kg,
open diamonds, n = 8; 5 mg/kg, open triangles, n = 7) or a vehicle control (n = 8). Error bars represent the s.e.m. EAE data is combined from 2
separate experiments. (C) CD45 and CD4 stained frozen brain sections (hippocampal area) from day 10 post-EAE induction SCH58261 and vehicle
treated wild type mice. Positively stained cells (red) are shown against a hematoxylin counterstain (blue). Black scale bars represent 50 μm. (D) Brain
CX3CL1 expression over time in wild type mice induced to develop EAE and given either SCH58261 or a vehicle control as determined by quantitative
real-time PCR. Error bars represent the s.e.m. Significant differences (P < 0.001, ***) are indicated as determined by the Student’s t-test.
Table 1 CD73−/− mice develop less severe EAE compared
to WT miceA
IncidenceB Mean Day of OnsetC Mean Max EAE ScoreD
WT 8/8 10.8 (8 – 14) 2.9 (1.5 – 5.0)
CD73−/− 6/10 12.7 (9 – 17) 1.1 (0.0 – 2.0) *
A. Wild type and CD73−/− mice were induced to develop EAE and scored
daily for EAE severity based on the 5 point scale assessing ascending paralysis.
B. Indicates the number of mice that achieved a score of 0.5 (weak tail) in the
experimental group.
C. Indicates the average day of onset for the mice that developed EAE (a score
of 0.5) followed by the range of scores in parentheses. Mice that did not
develop disease were excluded.
D. Indicated the average of the maximum EAE score for each individual mouse
followed by the range of scores in parentheses (* = p < 0.01; Student’s T-test).
Mills et al. Journal of Neuroinflammation 2012, 9:193 Page 6 of 12
http://www.jneuroinflammation.com/content/9/1/193
The choroid plexus is located within the ventricles of
the brain. It produces cerebral spinal fluid (CSF) and is
considered the blood to CSF barrier. Importantly, many
reports have indicated the importance of the choroid
plexus in both CNS lymphocyte infiltration and EAE
progression [23,24,34]. Additionally, the choroid plexus
has been shown to express CD73 and the A2A adeno-
sine receptor [20], giving it the capacity to produce and
respond to extracellular adenosine. To determine if ad-
enosine receptor activation modulates CX3CL1 on the
choroid plexus, we treated the CPLacZ-2 choroid plexus
epithelial cell line [32] with varying doses of the A2A ad-
enosine receptor agonist CGS21680 (Figure 3N). Indeed,
A2A adenosine receptor activation induced CX3CL1 ex-
pression on the choroid plexus cell line 2 hours post
treatment (Figure 3N). Furthermore, as CGS 21680
Figure 3 CX3CL1 expression in the brain during EAE progression. (A) Brain CX3CL1 expression of wild type mice with EAE as determined by
quantitative real-time PCR. Gene levels were normalized to GAPDH levels and are displayed as levels relative to naïve mice. Error bars represent
the s.e.m. (n = 5 mice per group). (B-M) Brains from naïve wild type mice were harvested and frozen for immunostaining. CX3CL1 expression
(red) and DAPI nuclei staining (blue) in (B, F, J) naïve and (C, G, K) Day 10, (D, H, L) Day 14, and (E, I, M) Day 21 post-EAE induced wild type mice.
CX3CL1 expression is displayed at the (B-E) choroid plexus, (F-I) in and near the hippocampus, and (J-M) cerebellum. White scale bars represent
50 μm. (N) CX3CL1 expression (relative to non-treated cells) in the CPLacZ-2 mouse choroid plexus cell line after 2 hour treatment with varying
concentrations of the A2A adenosine receptor specific adenosine receptor agonist CGS21680. Error bars represent the s.e.m. (O) Lymphocyte
migration across a transwell choroid plexus barrier following pretreatment with vehicle treatment alone, CGS21680, or CGS21680 and anti-CX3CL1.
Total migration was normalized to the vehicle control (set to 100%). Error bars represent the s.e.m. These results are representative of two separate
experiments (n ≤ 3).
Mills et al. Journal of Neuroinflammation 2012, 9:193 Page 7 of 12
http://www.jneuroinflammation.com/content/9/1/193
treatment of CPLacZ-2 cells seeded transwells was able
to promote lymphocyte transmigration, anti-CX3CL1
antibody treatment effectively inhibited this migration
(Figure 3O). In total, these results suggest that CX3CL1
expression on the choroid plexus is modulated by extra-
cellular adenosine to promote lymphocyte migration
into the CNS during EAE progression.
CX3CL1 blockade protects mice from EAE and its
associated CNS lymphocyte infiltration
Since our data suggests that extracellular adenosine and
adenosine receptor signaling regulate CX3CL1 expres-
sion to modulate lymphocyte infiltration into the CNS
during EAE progression, it is important to determine
the importance of CX3CL1 during EAE development.
Therefore, we analyzed the expression of CX3CR1 (the
receptor for CX3CL1) on immune cells that are known
to infiltrate the CNS during EAE and have a role in dis-
ease progression. Flow cytometric analysis of CX3CR1-
GFP mice [29] showed that CX3CR1 expression was
found on subsets of CD4, CD8, CD11b, F480 (macro-
phages), and CD49b (NK cells) positive cells (Figure 4).
CX3CR1 was not expressed on B220 (B cells) positive
cells (Figure 4). These results suggest that many immune
cells subtypes have the ability to respond to the chemo-
kine/adhesion molecule CX3CL1.
To determine if CX3CL1 activity is important for EAE
progression, wild type mice induced to develop EAE were
given daily i.p. injections of anti-CX3CL1 (neutralizing
antibody) or an isotype control antibody starting at Day 8
post-EAE induction (as increases in CX3CL1 are observed
during EAE beginning at Day 10) (Figure 5). Based on dis-
ease progression, wild type mice that received the anti-
CX3CL1 antibody were significantly protected from EAE
development, while those that received the control anti-
body treatment developed significant disease (Figure 5A).
Upon examination of the brains and spinal cords from
these EAE mice by IHC analysis, we observed fewer im-
mune cells in the CNS of anti-CX3CL1 treated mice com-
pared to control mice (Figure 5B-D). Specifically, while
wild type mice that received control antibody treatments
showed prominent CD45, CD11b, and F480 positive cell
staining in their brain (near the hippocampus and in
the cerebellum) and spinal cord, anti-CX3CL1 treated
mice displayed minimal staining for the same markers
(Figure 5B). Based on cell counts, anti-CX3CL1 treated
mice also had significantly fewer CD4 (Figure 5C) and
CD8 (Figure 5D) T-cells in their brain and spinal cord
(CD4 counts only) compared to control treated mice. It
should be noted that no CD49b (NK cell) staining was
observed in the brains of anti-CX3CL1 or control trea-
ted mice. These results indicate that CX3CL1 plays an
important role in the progression of EAE and lympho-
cyte infiltration into the CNS during disease develop-
ment. Overall, the data presented here suggest that
extracellular adenosine signaling in the CNS induces
CX3CL1 expression to induce lymphocyte migration
into the CNS to modulate EAE.
Discussion
The results presented here strongly suggest that extra-
cellular adenosine is an endogenous modulator of
lymphocyte migration into the CNS. Because adenosine
is an evolutionarily conserved molecule across many
species, many innate systems have evolved around the
presence of adenosine. Two of these systems are the im-
mune system and the CNS. While extracellular adeno-
sine has a wide variety of effects throughout the body,
the fact that it only has a half-life of approximately 6
seconds indicates that extracellular adenosine can only
have local effects [38,39]. Here we propose that the pres-
ence of high levels of extracellular adenosine within the
CNS act as a signal for cellular damage [40,41]. Our data
suggest that these high levels are detected by the A2A
Figure 4 The CX3CR1 receptor for CX3CL1 is expressed on immune cells. CX3CR1 expression was assessed on leukocytes isolated from the
spleens of naïve mice that express GFP driven by the CX3CR1 promoter (CX3CR1-GFP/GFP mice). Cells were stained with antibodies against CD4,
CD8, B220 (B cells), CX11b, F480 (macrophages), and CD49b (NK cells) and analyzed via flow cytometry. The antibody positive gated populations
are displayed as histograms with the percentage of CX3CR1 expressing cells within that population noted above each histogram subgate. These
results are representative of two separate experiments (n = 4 mice).
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adenosine receptor expressed at the choroid plexus
[20], which induces the expression of the chemokine/
adhesion molecule CX3CL1. Subsequent cleavage by
ADAM-10 and/or ADAM-17 [42] creates a CX3CL1
concentration gradient from which CX3CR1 expressing
cells chemotax to and gain entry into the CNS [43].
While previous findings indicated that extracellular ad-
enosine plays a vital role in neuroinflammation [20], its
role in regulating CX3CL1 expression in the CNS was in-
triguing. Our methodology for detecting genes regulated
by extracellular adenosine during neuroinflammation
involved 1) identifying genes (previously shown to have
a role in EAE development) that were differentially
expressed in CD73−/− compared to wild type mice fol-
lowing EAE induction and 2) determining which of these
genes were also induced in the CNS of mice following
adenosine receptor agonist treatments. Although other
genes displayed differential expression patterns between
wild type and CD73−/− mice during EAE progression
(i.e. CCL12, ICAM-1, CXCL9, CXCL10, CXCL12, etc),
CX3CL1 was of interest because it was both upregulated
in the brain in wild type but not CD73−/− mice and can
be dose-dependently induced in the brain of wild type
mice given adenosine receptor agonist treatment. Similar
to our findings, other studies have reported that CX3CL1
is involved in EAE and neuroinflammation [26-28,44].
Figure 5 CX3CL1 antibody mediated blockade protects mice against EAE and its associated lymphocyte infiltration. Wild type mice
were induced to develop EAE and starting at day 8 post induction given daily anti-CX3CL1 antibody or an isotype control treatments (i.p.). (A)
EAE disease profile. Error bars represent the s.e.m. (n = 4 mice/group). Significant differences are indicated as determined by two-way ANOVA.
EAE scoring data is representative of 2 separate experiments. (B) CD45, CD11b, and F480 stained brain (hippocampal and cerebellum areas) and
spinal cord sections from day 28 post-EAE induced mice treated with either anti-CX3CL1 or control antibody. Positively stained cells (red) are
shown against a hematoxylin counterstain (blue). Black scale bars represent 50 μm. (C) CD4 and (D) CD8 positive mean cells counts per field at
10x magnification from brain and spinal cord stained frozen brain sections from day 28 post-EAE induced mice treated with either anti-CX3CL1 or
control antibody. Error bars represent the standard error of the mean (n ≤ 11). Significant differences (P < 0.05, *) are indicated as determined by
the Student’s t-test.
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For example, increased CX3CL1 expression was observed
in the CNS of rats with EAE in inflammatory lesions [44].
Additionally, elevated CX3CL1 serum levels have been
reported in clinical studies in patients with neuroinflam-
matory diseases, with a positive correlation between
CX3CL1 expression and the frequency of lymphocytes in
the CSF [27,28]. Furthermore, CX3CR1 expressing cells
(which migrate in response to chemotactic CX3CL1 gra-
dients) have been shown to accumulate in brain lesions
of MS patients [26]. Overall, these results strongly suggest
that CX3CL1 may play a major and complex role in me-
diating lymphocyte migration into the CNS.
However, the role of CX3CL1 in neuroinflammation is
controversial. While the data we present here indicate
that CX3CL1 is involved in the triggering events leading
to immune cell entry into the CNS, others suggest that it
is involved in limiting the degree of inflammation within
the brain. These studies describing CX3CL1’s protective
role in neuroinflammation utilized the CX3CR1 null
mouse and EAE [45,46]. These studies showed that the
CX3CR1 null mice develop severe EAE due to a lack of
NK cells homing to the CNS [45]. These resident
CX3CR1+ NK cells (i.e. present before neuroinflamma-
tion) help to limit exacerbated neuroinflammation by
interacting with microglial cells and suppressing myelin-
reactive Th17 cells [46]. We believe that the results pre-
sented in our study do not contradict these previous
findings. In fact, since we utilize antibody blockade
(which protects against EAE development) and not gen-
etic disruption of the CX3CL1/CX3CR1 axis, our find-
ings further support the idea that CX3CL1 plays an
important role in neuroinflammation.
Our study also provides strong evidence that extracel-
lular adenosine is a triggering molecule for inducing
lymphocyte entry into the CNS. Previous studies have
identified the importance of A1 and A2A adenosine
receptors in the progression of EAE [20,47,48]. For in-
stance, mice that lack the A1 adenosine receptor are
prone to developing severe EAE [47,48], while mice that
receive A2A adenosine receptor antagonists (such as
SCH58261) [20,47] are protected against EAE develop-
ment and its associated lymphocyte infiltration. Interest-
ingly, the A1 and A2A adenosine receptor subtypes are
functionally antagonistic to each other and have different
affinities for extracellular adenosine [49]. For example,
A2A activation (which inhibits adenylate cyclase) only
occurs when extracellular adenosine levels reach a
higher concentration than required for A1 adenosine re-
ceptor activation (which stimulates adenylate cyclase)
[35,36]. Since the A1 and A2A adenosine receptors are
expressed on the choroid plexus [20], which is highly
involved in lymphocyte entry into the CNS [50], neu-
roinflammation within the CNS may depend on which
adenosine receptor is triggered on the choroid plexus.
These results suggest that the choroid plexus may act as
an adenosine concentration sensor, where high levels of
extracellular adenosine (which are produced following
cell damage) activate the A2A adenosine receptor and
induce lymphocyte infiltration into the CNS.
Despite our results which show the importance of ad-
enosine receptor signaling and CX3CL1 expression at the
choroid plexus during EAE, it cannot be overlooked that
other areas in the brain may also be involved in regulating
neuroinflammation. For example, the blood brain barrier,
which consists of astrocytes, pericytes, and endothelial
cells, has been shown to be an entry point for immune
cells during EAE progression [23,51,52]. Additionally,
both astrocytes and endothelial cells have been shown to
express adenosine receptors [21,53] suggesting that the
blood brain barrier can be influenced by increases in
extracellular adenosine levels. Interestingly, since CX3CL1
expression has been observed in astrocytes [44], this sug-
gests that CX3CL1 may be accessible at the blood brain
barrier to help promote lymphocyte migration into the
CNS during EAE. Additionally, in some instances (such as
ischemic brain injuries), adenosine receptor signaling has
been shown to be protective against neuroinflammation
[54]. Therefore, adenosine’s influence in the brain and on
CX3CL1 expression levels during neuroinflammation is a
more complex phenomenon than simply described here.
Overall, our study suggests that extracellular adeno-
sine receptor signaling is involved in the development
of neuroinflammation. By understanding the underlying
mechanisms involved in inducing migration during
cerebral inflammation, we show that directed blockade
of CX3CL1 can protect against disease development.
As cell damage events (i.e. leakage of ATP from com-
promised membranes) occur in almost all species, the
disease protection observed here in mice may be trans-
latable into new therapies for human patients with neu-
roinflammatory disorders. In fact, drugs used to inhibit
lymphocyte migration into the CNS (natalizumab) are
currently being used to treat MS [55]. However, the
shortcoming of drugs that completely inhibit lympho-
cyte migration (i.e. through blockade of the alpha-4 in-
tegrin) is the consequential induction of temporary
immunodeficiency in patients. For example, a well
reported potential danger of using natalizumab is the
increased risk of progressive multifocal leukoencephalo-
pathy (PML) and other opportunistic infections [55].
Therefore, a better approach in treating neuroinflam-
matory diseases may be to inhibit certain, but not all,
lymphocyte subsets from entering into the CNS (i.e. if
MS is caused by a bacterial/viral infection within the
CNS). Therefore, by understanding how and why cells
are induced to migrate into the CNS, new treatments
can be designed for patients with neuroinflammatory
disorders. The data presented here mark the continued
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steps of a journey that will lead to new therapies for
MS and other neuroinflammatory diseases.
Conclusions
We conclude that extracellular adenosine is an endogen-
ous modulator of neuroinflammation during EAE that
induces CX3CL1 at the choroid plexus to trigger
lymphocyte entry into the brain. This work signifies that
adenosinergic agents and the chemokines they induce
have the potential to be used in the treatments of neu-
roinflammatory diseases where pathogenic immune cell
entry into the CNS plays a major role.
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